Merck Sharp + Dohme Corp.

Merck + Co., Inc.

Albany Molecular Research, Inc.

Linus S Lin

William K Hagmann

Ravi P Nargund

Ping Liu

Shrenik K Shah

Linda L Chang

James Patrick Jewell

Marc D Chioda

Peter Guzzo

Iyassu Sebhat

Harry R Chobanian

Richard A Mumford

Christopher L Franklin

Jian Liu

Ravindra N Guthikonda

Robert J DeVita

Yan Guo

Thomas J Lanza, Jr

Hongbo Qi

Helen M Armstrong

David Chen

George A Doherty

Hubert B Josien

Qun Dang

Bin Hu

Mark T Goulet

Purakkattle J Biju

Bing Li

Zhengxia Chen

George A Doss

Timothy Allen Blizzard

Terence G Hamill

Mingxiang Cui

Wenji Yin

Sanjeev Kumar

Nicholas D Smith

Barbara A Pio

Kathleen M Rupprecht

Nicholas Simon Stock

Shuwen He

Robert K Baker

Theodore M Kamenecka

Bowei Wang

Ying-Duo Gao

Derun Li

Thomas S Reger

Christopher W Plummer

Shouwu Miao

Bruce Sargent

Alan John Henderson

Meibi Dai

Mark Hadden

Jason W Szewczyk

Tianying Jian

H Donald Burns

Raymond E Gibson

Dann Parker

Jinglai Hao

Jasmine Eleanor Zunic

Candido Gude

Allan James Goodman

Cheng Guo

Andrey V Peresypkin

Alex Minhua Chen

Ginger Xu-Qiang Yang

Larry Yet

Wenping Li

Peter H Dobbelaar

Zaihong Zhang

Ying Lv

Megan Ruenz

Lili Tian

Laurie A Castonguay

Michael M-c Lo

Michael M -c Lo

Michael M C Lo

Robert J Devita

George Doss

Thomas J Lanza

The present invention relates to a compound represented by formula (I): and pharmaceutically acceptable salts thereof. The compounds of formula I are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia. 

Antidiabetic substituted heteroaryl compounds

Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia. 

Antidiabetic tricyclic compounds

The present invention is directed to certain oxazole derivatives which are useful as inhibitors of Fatty Acid Amide Hydrolase (FAAH). The invention is also concerned with pharmaceutical formulations comprising these compounds as active ingredients and the use of the compounds and their formulations in the treatment of certain disorders, including osteoarthritis, rheumatoid arthritis, diabetic neuropathy, postherpetic neuralgia, skeletomuscular pain, and fibromyalgia, as well as acute pain, migraine, sleep disorder, Alzheimer Disease, and Parkinson's Disease.

Oxazole derivatives useful as inhibitors of FAAH

The present invention is directed to certain Inidazole derivatives which are useful as modulators of Fatty Acid Amide Hydrolase (FAAH) and as FAAH imaging agents. The invention is also concerned with pharmaceutical formulations comprising these compounds as active ingredients and the use of the compounds and their formulations in the treatment of certain disorders, including osteoarthritis, rheumatoid arthritis, diabetic neuropathy, postherpetic neuralgia, skeletomuscular pain, and fibromyalgia, as well as acute pain, migraine, sleep disorder, Alzeimer Disease, and Parkinson's Disease.

Imidazole derivatives useful as modulators of FAAH and as FAAH imaging agents

The present invention is directed to certain imidazole derivatives which are useful as inhibitors of Fatty Acid Amide Hydrolase (FAAH). The invention is also concerned with pharmaceutical formulations comprising these compounds as active ingredients and the use of the compounds and their formulations in the treatment of certain disorders, including osteoarthritis, rheumatoid arthritis, diabetic neuropathy, postherpetic neuralgia, skeletomuscular pain, and fibromyalgia, as well as acute pain, migraine, sleep disorder, Alzeimer Disease, and Parkinson's Disease.

Imidazole derivatives useful as inhibitors of FAAH

Certain novel substituted imidazoles are ligands of the human bombesin receptor and, in particular, are selective ligands of the human bombesin receptor subtype-3 (BRS-3). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the modulation of BRS-3, such as obesity, and diabetes.

Substituted imidazoles as bombesin receptor subtype-3 modulators

Substituted imidazole as bombesin receptor subtype-3 modulators

Certain novel substituted diazepine sulfonamides are ligands of the human bombesin receptor and, in particular, are selective ligands of the human bombesin receptor subtype-3 (BRS-3). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the modulation of BRS-3, such as obesity, and diabetes. 

Substituted diazepine sulfonamides as bombesin receptor subtype-3 modulators

Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.

Substituted amides

The present invention relates to particular radiolabeled Cannabinoid-1 (CB1) receptor modulators, and methods of using these modulators for labeling and diagnostic imaging of Cannabinoid-1 receptors in mammals, particularly humans. In addition, intermediates useful for the synthesis of the radiolabeled Cannabinoid-1 receptor modulators are also disclosed, as well as the processes for synthesizing the radiolabeled Cannabinoid-1 receptor modulators. Still further, formulations of the radiolabeled Cannabinoid-1 receptor compounds are described.

Radiolabeled cannabinoid-1 receptor modulators

Bicyclic amides

Growing community of inventors

Westfield, NJ, United States of America

Linus S Lin